Abstract
Background: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis.
Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion: HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer.Keywords: HE4, gynecologic cancers, ovarian cancers, endometrial cancers, cancer recurrence, prognosis.
Current Drug Targets
Title:Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers
Volume: 18 Issue: 10
Author(s): Jinping Li, Haibin Chen, John R. Curcuru, Sheena Patel, Taylor O. Johns, Dimple Patel, Hua Qian*Shi-wen Jiang*
Affiliation:
- Department of Obstetrics and Gynecology, the Taizhou People's Hospital, Taizhou 225300, Jiangsu,China
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, China / Department of Biomedical Science, Mercer University School of Medicine, Savannah, Georgia 31404,United States
Keywords: HE4, gynecologic cancers, ovarian cancers, endometrial cancers, cancer recurrence, prognosis.
Abstract: Background: HE4 may be a valuable early indicator of the recurrence of gynecologic cancers. Numerous studies have shown that high expression levels of serum HE4 correlate with ovarian and endometrial cancer recurrence. High HE4 levels may be an independent factor to predict these cancers’ poor prognosis.
Objective: This literature review investigates the relationship between serum HE4 levels and the recurrence of ovarian and endometrial cancer. Conclusion: HE4 displays malignant behavior by promoting cancer cells to skip from G1 phase to S phase, maintaining cell viability, encouraging cell proliferation, inhibiting cell apoptosis, and increasing resistance to drug treatments. Further studies are required to verify that elevated serum HE4 levels correlate with the recurrence of ovarian and endometrial cancer.Export Options
About this article
Cite this article as:
Li Jinping, Chen Haibin, Curcuru R. John, Patel Sheena, Johns O. Taylor, Patel Dimple, Qian Hua*, Jiang Shi-wen *, Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170404154929
DOI https://dx.doi.org/10.2174/1389450118666170404154929 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry The Pleiotropic Effects of PPARs on Vascular Cells and Angiogenesis: Implications for Tissue Engineering
Current Stem Cell Research & Therapy Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Vaginitis Due to <i>Pichia fermentans</i> in a Patient Affected by Endometrial Cancer: A Novel Case Report
Current Women`s Health Reviews Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents On Electromagnetic Ablation of Biological Tissues: A Review
Recent Patents on Electrical Engineering Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Novel Ligands: Fine Tuning the Transcriptional Activity of the Glucocorticoid Receptor
Current Pharmaceutical Design Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: A Review on Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Adipose Tissue: Something More than Just Adipocytes
Current Nutrition & Food Science Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Current Drug Targets Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry